Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
March 16, 2022 at 12:38 am EDT
Share
Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with KB Securities (KB Securities Co., Ltd.). The purpose of the program is to improve shareholder value and stock price stabilization.
The program will expire on September 16, 2022. As of March 15, 2022, the company had no shares in treasury within scope available for dividend and no shares in treasury under other capacities.
HWAIL PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. It also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The Company distributes its products within domestic market and to overseas markets.
HWAIL PHARMACEUTICAL CO.,LTD. 
